NovaBridge Biosciences
NBP
$4.26
-$0.01-0.23%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -18.37M | -35.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -18.37M | -35.13M |
| Cost of Revenue | -- | -- | -- | 0.00 | 2.06M |
| Gross Profit | -- | -- | -- | -18.37M | -37.19M |
| SG&A Expenses | -- | -- | -- | 59.08M | 97.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 124.85M | 203.13M |
| Operating Income | -- | -- | -- | -143.22M | -238.26M |
| Income Before Tax | -- | -- | -- | -145.25M | -296.33M |
| Income Tax Expenses | -- | -- | -- | 49.00K | 99.90K |
| Earnings from Continuing Operations | -- | -- | -- | -145.30 | -296.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -68.24M | -34.33M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -213.54M | -330.76M |
| EBIT | -- | -- | -- | -143.22M | -238.26M |
| EBITDA | -- | -- | -- | -139.66M | -234.63M |
| EPS Basic | -- | -- | -- | -5.91 | -9.20 |
| Normalized Basic EPS | -- | -- | -- | -1.05 | -2.15 |
| EPS Diluted | -- | -- | -- | -5.91 | -9.20 |
| Normalized Diluted EPS | -- | -- | -- | -1.05 | -2.15 |
| Average Basic Shares Outstanding | -- | -- | -- | 332.41M | 331.05M |
| Average Diluted Shares Outstanding | -- | -- | -- | 144.53M | 143.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |